Related Experiment Video
Updated: Nov 9, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Hypertrophic cardiomyopathy: diagnosis and therapeutic options
1Center for Cardiovascular Analytics, Research and Data Science (CARDS), Providence Heart Institute, Portland, OR.
Insights
Hypertrophic cardiomyopathy, a genetic disorder from sarcomeric protein mutations, presents variably. Current treatments manage symptoms and prevent sudden death, with new therapies under investigation.
Area of Science:
- Cardiology
- Genetics
- Molecular Biology
Background:
- Hypertrophic cardiomyopathy (HCM) is an underdiagnosed genetic disorder caused by sarcomeric protein mutations.
- HCM is characterized by left ventricular hypertrophy unexplained by other cardiac conditions.
- Clinical presentation varies widely, from asymptomatic cases to severe functional limitations.
Purpose of the Study:
- To review the current understanding of hypertrophic cardiomyopathy.
- To discuss diagnostic classifications, including outflow tract obstruction.
- To summarize existing therapeutic strategies and emerging treatments.
Main Methods:
- Review of existing literature on hypertrophic cardiomyopathy.
- Analysis of clinical presentations and diagnostic criteria.
- Evaluation of current and investigational pharmacologic therapies.
Main Results:
- HCM is a genetically heterogeneous condition with diverse clinical outcomes.
- Current therapies focus on symptom management and sudden cardiac death prevention.
- No treatments currently alter the disease's natural progression.
Conclusions:
- Hypertrophic cardiomyopathy requires ongoing research for effective disease-modifying therapies.
- Accurate diagnosis and classification are crucial for patient management.
- Investigational therapies hold promise for improving patient symptoms and quality of life.
Abstract:
Hypertrophic cardiomyopathy is an underdiagnosed genetic disorder, resulting from mutations in sarcomeric proteins. It has a highly variable clinical presentation, with some individuals remaining asymptomatic and others having significant limitation of functional status. The disorder is typically characterized by left ventricular hypertrophy that is not explained by another cause. Patients are further classified based on whether there is obstruction of the left ventricular outflow tract. To-date, there are no pharmacologic therapies that alter the natural history of the disease. Therapeutic approaches have instead focused on symptom relief and prevention of sudden cardiac death. Newer therapies under investigation represent potential means to improve limiting symptoms.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Myocarditis III: Medical Management

